|Bid||58.30 x 200|
|Ask||59.39 x 500|
|Day's Range||58.42 - 59.32|
|52 Week Range||52.83 - 66.41|
|PE Ratio (TTM)||67.40|
|Earnings Date||May 1, 2018|
|Forward Dividend & Yield||1.92 (3.36%)|
|1y Target Est||66.50|
Merck KGaA’s products include Femibion, a supplement for women. A Business News article in some editions Thursday about the sale of Merck KGaA’s consumer-health unit to Procter & Gamble Co. incorrectly ...
The FDA accepts Bristol-Myers Squibb's (BMY) supplemental Biologics License Application and grants priority review for the label expansion of Opdivo to treat patients with small cell lung cancer.
The maker of Pampers diapers and Gillette razors said the deal would help it expand its portfolio of consumer healthcare products which includes Vicks cold relief. The Merck unit includes vitamin brands Femibion and Neurobion. The deal follows GlaxoSmithKline agreeing to buy Novartis out of their consumer healthcare joint venture for $13 billion after dropping its pursuit of Pfizer's consumer unit.
P&G is fresh off a big deal on Thursday. TheStreet talks with one of the company's top executives about the transaction.
European dietary supplements won’t cure what ails Procter & Gamble. The consumer products maker should focus on fixing its core business to resume growth.
FRANKFURT, Germany (AP) — German pharmaceutical and chemical company Merck says it has agreed to sell its global consumer health business to Procter & Gamble for 3.4 billion euros ($4.2 billion) in cash.
Fresh off the news of a $4.2 billion acquisition of Merck KGaA’s consumer unit, Procter & Gamble Co. reported higher sales and said more change is on the way. P&G shares declined on Thursday as investors hungry for deeper change brushed aside higher revenue in the latest quarter. It’s betting that the vitamins and decongestants obtained in the purchase of Merck’s unit will hasten its comeback.
Procter & Gamble Co. agreed to buy Merck KGaA’s consumer-health business for 3.4 billion euros ($4.2 billion) to bolster growth, betting that vitamins and decongestants can hasten its comeback. The deal gives the maker of Crest toothpaste a stable of products with sales growth of 6 percent in the past two years, double the pace of traditional consumer goods such as razors, diapers and tissues. German drugmaker Merck put the the unit up for sale last year as it pumps money into testing new medicines.
Piper Jaffray reiterates eBay (NASDAQ: EBAY ) Overweight rating and $89 price target following news of Amazon partnership; Says it's a very smart win-win relationship and believes it will be a revenue ...
- Cell therapies an emerging treatment modality, expected to blossom into $25 billion-plus industry within a decade. Manufacturing is complex, costing $50K+ per patient, and many companies turn to contract manufacturers for help with development and commercial readiness. NEW YORK, NY / ACCESSWIRE / April 18, 2018 / Cell therapies are lined up to be one of the largest new biomedical breakthroughs in decades.
In 4Q17, AbbVie’s (ABBV) Duodopa generated revenue of $100 million, marking ~28% growth YoY (year-over-year) and 6% growth quarter-over-quarter. In US and international markets, Duodopa saw revenue of $17 million and $77 million, respectively, reflecting ~55.2% and ~23% growth YoY.
Hours after markets closed on Bristol-Myers Squibb Co.’s worst day in more than a year, executives used a sugary analogy to explain to Wall Street why the drugmaker’s new cancer treatment would do just ...
Merck & Co., Inc. (NYSE: MRK )’s Keytruda returned better-than-expected results in the Keynote-189 lung study — a feat seen to lend a competitive edge over Bristol-Myers Squibb Co (NYSE: BMY ). The Rating ...
Merck (MRK) releases complete data from a phase III study showing Keytruda in combination with Lilly's Alimta and platinum chemotherapy reducing death risk by half compared with only chemotherapy.
Bristol-Myers (BMY) stock declined as the company reported encouraging results from its NSCLC study but competitor Merck scored better in the same regard.
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.
Headquartered in Basel, Switzerland, Novartis (NVS) is one of the largest pharmaceutical companies by revenue. Novartis specializes in the development, manufacturing, and marketing of healthcare products.
Merck , known as MSD outside of the United States and Canada, today announced that the company is beginning two Phase 3 studies of PCV-15 , its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.
NEW YORK, NY / ACCESSWIRE / April 17, 2018 / Nektar shares closed lower on Monday as the company is presenting new preclinical data for its immuno-oncology programs at the American Association for Cancer ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $19.20 billion.
The pairing of Keytruda and chemotherapy reduced risk of death for patients with advanced lung cancer by half, a significant improvement.
Apr.19 -- Bloomberg's Heather Burke discusses Unilever strategies, m&a and the business model for advertising agencies. She speaks with Mark Barton on "Bloomberg Markets."